Skip to main content
SpringerLink
Log in

Adipokines and Prostate Cancer

  • Chapter
  • First Online:
Energy Balance and Prostate Cancer

Part of the book series: Energy Balance and Cancer ((EBAC,volume 14))

  • 362 Accesses

Abstract

Adipokines (adipocytokines) have been suggested to play a role in the well-established association of obesity and prostate cancer. Adipokines are secreted by adipose tissue and dysregulated in obese individuals. Given their association with multiple pathways, it has been hypothesized that adipokines mediate the association between obesity and prostate cancer risk and aggressiveness. Mechanistic studies have provided good evidence of the role of leptin in prostate cancer cellular proliferation. In clinical studies, circulating levels of many adipokines have been associated with risk of prostate cancer, however many of these have been met with mixed results or suffered from small sample sizes, so there remains significant opportunities for more research in the area. In contrast, there has been evidence that inherited genetic variation in adipokines and their receptors may increase prostate cancer risk, with strong evidence particularly for LEP and TNFa. However, more studies in this area are needed as well. Although there is room for more research to understand the role of adipokines in clinical prostate cancer management, it is reasonable to hypothesize that adipokines can help manage the association between obesity and prostate cancer. With growing rates of obesity, in turn the impact of adipokines on prostate cancer risk and progression will increase. Thus, understanding adipokines in relation to prostate cancer may provide therapeutic and preventative measures to reduce the risk and progression of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol. 1984;120:244–50.

    Article  CAS  PubMed  Google Scholar 

  2. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15:1977–83.

    Article  PubMed  Google Scholar 

  3. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63–9.

    Article  PubMed  Google Scholar 

  4. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4:486–501.

    Article  CAS  Google Scholar 

  5. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46–53.

    Article  CAS  PubMed  Google Scholar 

  6. Leal Vde O, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013;419:87–94.

    Article  PubMed  Google Scholar 

  7. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.

    Article  CAS  PubMed  Google Scholar 

  8. Lee CH, Woo YC, Wang Y, et al. Obesity, adipokines and cancer: an update. Clin Endocrinol (Oxf). 2015;83:147–56.

    Article  CAS  Google Scholar 

  9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  10. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–55.

    Article  CAS  PubMed  Google Scholar 

  11. Mancuso P. The role of adipokines in chronic inflammation. Immunotargets Ther. 2016;5:47–56.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9. quiz 920

    Article  CAS  PubMed  Google Scholar 

  13. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68:437–46.

    CAS  PubMed  Google Scholar 

  14. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004;109:2046–9.

    Article  CAS  PubMed  Google Scholar 

  15. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630–5.

    Article  CAS  PubMed  Google Scholar 

  16. Beltowski J. Adiponectin and resistin—new hormones of white adipose tissue. Med Sci Monit. 2003;9:RA55–61.

    CAS  PubMed  Google Scholar 

  17. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34:2–11.

    Article  CAS  PubMed  Google Scholar 

  18. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.

    CAS  PubMed  Google Scholar 

  19. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:71.

    Google Scholar 

  20. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292–5.

    Article  CAS  PubMed  Google Scholar 

  22. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014;130:157–69.

    Article  CAS  PubMed  Google Scholar 

  23. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003;278:42660–7.

    Article  CAS  PubMed  Google Scholar 

  24. Somasundar P, Frankenberry KA, Skinner H, et al. Prostate cancer cell proliferation is influenced by leptin. J Surg Res. 2004;118:71–82.

    Article  CAS  PubMed  Google Scholar 

  25. Saglam K, Aydur E, Yilmaz M, Goktas S. Leptin influences cellular differentiation and progression in prostate cancer. J Urol. 2003;169:1308–11.

    Article  CAS  PubMed  Google Scholar 

  26. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001;86:1341–5.

    CAS  PubMed  Google Scholar 

  27. Stattin P, Kaaks R, Johansson R, et al. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:474–5.

    CAS  PubMed  Google Scholar 

  28. Baillargeon J, Platz EA, Rose DP, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev. 2006;15:1331–5.

    Article  CAS  PubMed  Google Scholar 

  29. He J, Xi B, Ruiter R, et al. Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis. PLoS One. 2013;8:e75135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Shi H, Shu H, Huang C, et al. Association of LEPR K109R polymorphisms with cancer risk: a systematic review and pooled analysis. J BUON. 2014;19:847–54.

    PubMed  Google Scholar 

  31. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.

    Article  CAS  PubMed  Google Scholar 

  32. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm Res. 2003;60(Suppl 3):56–9.

    CAS  PubMed  Google Scholar 

  33. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6:13–21.

    Article  CAS  PubMed  Google Scholar 

  34. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340:1158–66.

    Article  CAS  PubMed  Google Scholar 

  35. Tang CH, Lu ME. Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. Prostate. 2009;69:1781–9.

    Article  CAS  PubMed  Google Scholar 

  36. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007;14:995–1005.

    Article  CAS  PubMed  Google Scholar 

  37. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urology. 2005;65:1168–72.

    Article  PubMed  Google Scholar 

  38. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dhillon PK, Penney KL, Schumacher F, et al. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2618–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kaklamani V, Yi N, Zhang K, et al. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism. 2011;60:1234–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gu CY, Li QX, Zhu Y, et al. Genetic variations of the ADIPOQgene and risk of prostate cancer in Chinese Han men. Asian J Androl. 2014;16:878–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Beebe-Dimmer JL, Zuhlke KA, Ray AM, et al. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis. 2010;13:362–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Mistry T, Digby JE, Chen J, et al. The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun. 2006;348:832–8.

    Article  CAS  PubMed  Google Scholar 

  44. Mistry T, Digby JE, Desai KM, Randeva HS. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression. BJU Int. 2008;101:1317–22.

    Article  CAS  PubMed  Google Scholar 

  45. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tzanavari T, Giannogonas P, Karalis KP. TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–56.

    Article  CAS  PubMed  Google Scholar 

  47. Tse BW, Scott KF, Russell PJ. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer. 2012;2012:128965.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.

    Article  CAS  PubMed  Google Scholar 

  49. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29:1275–88.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Lett. 2004;203:145–54.

    Article  CAS  PubMed  Google Scholar 

  51. Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182–7.

    Article  CAS  PubMed  Google Scholar 

  52. Fargion S, Valenti L, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood. 2001;97:3707–12.

    Article  CAS  PubMed  Google Scholar 

  53. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-alpha gene polymorphisms and expression. Springerplus. 2016;5:1508.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Ma L, Zhao J, Li T, et al. Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014;9:74.

    Article  PubMed  PubMed Central  Google Scholar 

  55. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5(Suppl 1):3–10.

    Article  CAS  PubMed  Google Scholar 

  56. Sharif MR, Shaabani A, Mahmoudi H, et al. Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies. Nephrourol Mon. 2014;6:e14778.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Botelho F, Pina F, Lunet N. VEGF and prostatic cancer: a systematic review. Eur J Cancer Prev. 2010;19:385–92.

    Article  CAS  PubMed  Google Scholar 

  58. Langsenlehner T, Langsenlehner U, Renner W, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572–6.

    Article  CAS  PubMed  Google Scholar 

  59. VanCleave TT, Moore JH, Benford ML, et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010;70:341–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986–92.

    Article  CAS  PubMed  Google Scholar 

  61. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol. 2000;164:722–5.

    Article  CAS  PubMed  Google Scholar 

  62. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res. 2001;7:2941–8.

    CAS  PubMed  Google Scholar 

  63. Drachenberg DE, Elgamal AA, Rowbotham R, et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41:127–33.

    Article  CAS  PubMed  Google Scholar 

  64. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Pierce BL, Biggs ML, DeCambre M, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control. 2009;20:1193–203.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Chen J, Ying XM, Huang XM, et al. Association between polymorphisms in selected inflammatory response genes and the risk of prostate cancer. Onco Targets Ther. 2016;9:223–9.

    PubMed  PubMed Central  Google Scholar 

  67. Huang WJ, Wu LJ, Min ZC, et al. Interleukin-6-572G/C polymorphism and prostate cancer susceptibility. Genet Mol Res. 2016;15:447–53.

    Google Scholar 

  68. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88–97.

    Article  PubMed  Google Scholar 

  69. Hoda MR, Theil G, Mohammed N, et al. The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J Oncol. 2012;2012:280386.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Noda T, Kikugawa T, Tanji N, et al. Longterm exposure to leptin enhances the growth of prostate cancer cells. Int J Oncol. 2015;46:1535–42.

    Article  CAS  PubMed  Google Scholar 

  71. Ribeiro AM, Pereira S, Andrade S, et al. Insulin prevents leptin inhibition of RM1 prostate cancer cell growth. Pathol Oncol Res. 2012;18:499–507.

    Article  CAS  PubMed  Google Scholar 

  72. Moreira A, Pereira SS, Costa M, et al. Adipocyte secreted factors enhance aggressiveness of prostate carcinoma cells. PLoS One. 2015;10:e0123217.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Burton A, Martin RM, Holly J, et al. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control. 2013;24:323–34.

    Article  PubMed  Google Scholar 

  74. Sher DJ, Oh WK, Jacobus S, et al. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008;68:1592–8.

    Article  CAS  PubMed  Google Scholar 

  75. Freedland SJ, Sokoll LJ, Platz EA, et al. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol. 2005;174:1266–70.

    Article  CAS  PubMed  Google Scholar 

  76. Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2014;23:890–2.

    Article  CAS  PubMed  Google Scholar 

  77. Bao B, Ahmad A, Kong D, et al. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 2012;7:e43726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lin DW, FitzGerald LM, Fu R, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011;20:1928–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34–43.

    Article  CAS  PubMed  Google Scholar 

  80. Gu C, Qu Y, Zhang G, et al. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. Oncotarget. 2015;6:32205–11.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Duque JL, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523–7.

    Article  CAS  PubMed  Google Scholar 

  82. Erkal EY, Bora H, Tepeoglu M, Akmansu M. Role of vascular endothelial growth factor in clinically localized prostate cancer treated with radiation therapy. Balkan Med J. 2014;31:43–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Wu TT, Wang JS, Jiann BP, et al. Expression of vascular endothelial growth factor in Taiwanese benign and malignant prostate tissues. J Chin Med Assoc. 2007;70:380–4.

    Article  PubMed  Google Scholar 

  84. Roberts E, Cossigny DA, Quan GM. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer. 2013;2013:418340.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Liu ZQ, Fang JM, Xiao YY, et al. Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:2289–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Pan L, Baek S, Edmonds PR, et al. Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610. Radiat Oncol. 2013;8:100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Orlandi P, Fontana A, Fioravanti A, et al. VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer. 2013;109:957–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702–6.

    CAS  PubMed  Google Scholar 

  89. Shariat SF, Andrews B, Kattan MW, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58:1008–15.

    Article  CAS  PubMed  Google Scholar 

  90. Zhang J, Pugh TD, Stebler B, et al. Orchiectomy increases bone marrow interleukin-6 levels in mice. Calcif Tissue Int. 1998;62:219–26.

    Article  CAS  PubMed  Google Scholar 

  91. Tsui KH, Lin YF, Chen YH, et al. Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells. J Androl. 2011;32:383–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nutrition, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106-4971, USA

    Cheryl L. Thompson

  2. Department of Anatomy, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA

    MacKenzie Reece

Authors
  1. Cheryl L. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. MacKenzie Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheryl L. Thompson .

Editor information

Editors and Affiliations

  1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

    Elizabeth A. Platz

  2. Center for Science, Health and Society, Case Western Reserve University, Cleveland, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Thompson, C.L., Reece, M. (2018). Adipokines and Prostate Cancer. In: Platz, E., Berger, N. (eds) Energy Balance and Prostate Cancer. Energy Balance and Cancer, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-319-64940-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64940-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64939-9

  • Online ISBN: 978-3-319-64940-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation